慢性疲労症候群治療薬の世界市場：2022年～2026年

世界の慢性疲労症候群治療薬の市場規模は、2022年から2026年の間に5,184万米ドル成長し、予測期間中は4.31％のCAGRで成長する見込みです。

市場を牽引するのは、CFSの適応外薬物療法の使用増加、CFSの危険因子の増加、CFSに関する認識を高める取り組みなどです。

当レポートでは、慢性疲労症候群治療薬の世界市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、および約25のベンダーをカバーする分析を提供しています。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場のエコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 2021年の市場規模
• 市場の見通し：2021年から2026年の予測

第4章 ファイブフォース分析

• ファイブフォースまとめ
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第5章 市場セグメンテーション：製品別

• 市場セグメント
• 製品別の比較
• 鎮痛剤およびNSAID：市場規模と予測（2021年～2026年）
• 抗うつ薬および抗精神病薬：市場規模と予測（2021年～2026年）
• 抗菌薬および免疫調節薬：市場規模と予測（2021年～2026年）
• 製品別の市場機会

第6章 顧客情勢

• 顧客情勢の概要

第7章 地域別情勢

• 地域別セグメンテーション
• 地域別の比較
• 北米：市場規模と予測（2021年～2026年）
• 欧州：市場規模と予測（2021年～2026年）
• アジア：市場規模と予測（2021年～2026年）
• その他の地域：市場規模と予測（2021年～2026年）
• 米国：市場規模と予測（2021年～2026年）
• ドイツ：市場規模と予測（2021年～2026年）
• 英国：市場規模と予測（2021年～2026年）
• カナダ：市場規模と予測（2021年～2026年）
• フランス：市場規模と予測（2021年～2026年）
• 地域情勢別の市場機会

第8章 推進要因、課題、および動向

• 市場推進要因
• 市場の課題
• 推進要因と課題の影響
• 市場動向

第9章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第10章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• AIM ImmunoTech Inc.
• Apotex Inc.
• Bionpharma Inc.
• Cadila Pharmaceuticals Ltd.
• Hikma Pharmaceuticals Plc
• Lupin Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

第11章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Product
• Exhibits6: Executive Summary - Chart on Incremental Growth
• Exhibits7: Executive Summary - Data Table on Incremental Growth
• Exhibits8: Executive Summary - Chart on Vendor Market Positioning
• Exhibits9: Parent market
• Exhibits10: Market Characteristics
• Exhibits11: Offerings of vendors included in the market definition
• Exhibits12: Market segments
• Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibits17: Five forces analysis - Comparison between 2021 and 2026
• Exhibits18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
• Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
• Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026
• Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026
• Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026
• Exhibits23: Chart on Market condition - Five forces 2021 and 2026
• Exhibits24: Chart on Product - Market share 2021-2026 (%)
• Exhibits25: Data Table on Product - Market share 2021-2026 (%)
• Exhibits26: Chart on Comparison by Product
• Exhibits27: Data Table on Comparison by Product
• Exhibits28: Chart on Pain relievers and NSAIDs - Market size and forecast 2021-2026 ($ million)
• Exhibits29: Data Table on Pain relievers and NSAIDs - Market size and forecast 2021-2026 ($ million)
• Exhibits30: Chart on Pain relievers and NSAIDs - Year-over-year growth 2021-2026 (%)
• Exhibits31: Data Table on Pain relievers and NSAIDs - Year-over-year growth 2021-2026 (%)
• Exhibits32: Chart on Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026 ($ million)
• Exhibits33: Data Table on Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026 ($ million)
• Exhibits34: Chart on Antidepressant and antipsychotic drugs - Year-over-year growth 2021-2026 (%)
• Exhibits35: Data Table on Antidepressant and antipsychotic drugs - Year-over-year growth 2021-2026 (%)
• Exhibits36: Chart on Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026 ($ million)
• Exhibits37: Data Table on Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026 ($ million)
• Exhibits38: Chart on Antimicrobial and immunomodulatory drugs - Year-over-year growth 2021-2026 (%)
• Exhibits39: Data Table on Antimicrobial and immunomodulatory drugs - Year-over-year growth 2021-2026 (%)
• Exhibits40: Market opportunity by Product ($ million)
• Exhibits41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits42: Chart on Market share By Geographical Landscape 2021-2026 (%)
• Exhibits43: Data Table on Market share By Geographical Landscape 2021-2026 (%)
• Exhibits44: Chart on Geographic comparison
• Exhibits45: Data Table on Geographic comparison
• Exhibits46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibits47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibits48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibits49: Data Table on North America - Year-over-year growth 2021-2026 (%)
• Exhibits50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibits51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibits52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibits53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
• Exhibits54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibits55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibits56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibits57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
• Exhibits58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibits59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibits60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibits61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibits62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibits63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibits64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibits65: Data Table on US - Year-over-year growth 2021-2026 (%)
• Exhibits66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibits67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibits68: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibits69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
• Exhibits70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibits71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibits72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibits73: Data Table on UK - Year-over-year growth 2021-2026 (%)
• Exhibits74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibits75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibits76: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibits77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
• Exhibits78: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibits79: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibits80: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibits81: Data Table on France - Year-over-year growth 2021-2026 (%)
• Exhibits82: Market opportunity By Geographical Landscape ($ million)
• Exhibits83: Impact of drivers and challenges in 2021 and 2026
• Exhibits84: Overview on Criticality of inputs and Factors of differentiation
• Exhibits85: Overview on factors of disruption
• Exhibits86: Impact of key risks on business
• Exhibits87: Vendors covered
• Exhibits88: Matrix on vendor position and classification
• Exhibits89: AIM ImmunoTech Inc. - Overview
• Exhibits90: AIM ImmunoTech Inc. - Product / Service
• Exhibits91: AIM ImmunoTech Inc. - Key offerings
• Exhibits92: Apotex Inc. - Overview
• Exhibits93: Apotex Inc. - Product / Service
• Exhibits94: Apotex Inc. - Key offerings
• Exhibits95: Bionpharma Inc. - Overview
• Exhibits96: Bionpharma Inc. - Product / Service
• Exhibits97: Bionpharma Inc. - Key offerings
• Exhibits98: Cadila Pharmaceuticals Ltd. - Overview
• Exhibits99: Cadila Pharmaceuticals Ltd. - Business segments
• Exhibits100: Cadila Pharmaceuticals Ltd. - Key offerings
• Exhibits101: Cadila Pharmaceuticals Ltd. - Segment focus
• Exhibits102: Hikma Pharmaceuticals Plc - Overview
• Exhibits103: Hikma Pharmaceuticals Plc - Business segments
• Exhibits104: Hikma Pharmaceuticals Plc - Key offerings
• Exhibits105: Hikma Pharmaceuticals Plc - Segment focus
• Exhibits106: Lupin Ltd. - Overview
• Exhibits107: Lupin Ltd. - Product / Service
• Exhibits108: Lupin Ltd. - Key news
• Exhibits109: Lupin Ltd. - Key offerings
• Exhibits110: Pfizer Inc. - Overview
• Exhibits111: Pfizer Inc. - Product / Service
• Exhibits112: Pfizer Inc. - Key news
• Exhibits113: Pfizer Inc. - Key offerings
• Exhibits114: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibits115: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibits116: Sun Pharmaceutical Industries Ltd. - Key offerings
• Exhibits117: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits118: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits119: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits120: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits121: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits122: Viatris Inc. - Overview
• Exhibits123: Viatris Inc. - Business segments
• Exhibits124: Viatris Inc. - Key offerings
• Exhibits125: Viatris Inc. - Segment focus
• Exhibits126: Inclusions checklist
• Exhibits127: Exclusions checklist
• Exhibits128: Currency conversion rates for US$
• Exhibits129: Research methodology
• Exhibits130: Validation techniques employed for market sizing
• Exhibits131: Information sources
• Exhibits132: List of abbreviations

Technavio has been monitoring the chronic fatigue syndrome therapeutics market and it is poised to grow by $ 51.84 million during 2022-2026, accelerating at a CAGR of 4.31% during the forecast period. Our report on the chronic fatigue syndrome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, challenges, and vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing use of off-label pharmacological treatment for CFS, increasing risk factors of CFS, and initiatives to increase awareness about CFS.

The chronic fatigue syndrome therapeutics market analysis includes product segment and geographic landscape.

Technavio's chronic fatigue syndrome therapeutics market is segmented as below:

By Product

• Pain relievers and NSAIDs
• Antidepressant and antipsychotic drugs
• Antimicrobial and immunomodulatory drugs

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the development of new diagnostic tests for CFS as one of the prime reasons driving the chronic fatigue syndrome therapeutics market growth during the next few years. Also, R&D of new drugs for the treatment of CFS and increasing focus on the investigation of the role of the immune system in CFS will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the chronic fatigue syndrome therapeutics market covers the following areas:

• Chronic fatigue syndrome therapeutics market sizing
• Chronic fatigue syndrome therapeutics market forecast
• Chronic fatigue syndrome therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic fatigue syndrome therapeutics market vendors that include AIM ImmunoTech Inc., Apotex Inc., Aurobindo Pharma Ltd., Bionpharma Inc., Cadila Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Lupin Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the chronic fatigue syndrome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Incremental Growth
• Exhibit 07: Executive Summary - Data Table on Incremental Growth
• Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 12: Market segments
• 3.3 Market size 2021
• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
• 5.2 Comparison by Product
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product
• 5.3 Pain relievers and NSAIDs - Market size and forecast 2021-2026
• Exhibit 28: Chart on Pain relievers and NSAIDs - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Pain relievers and NSAIDs - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Pain relievers and NSAIDs - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Pain relievers and NSAIDs - Year-over-year growth 2021-2026 (%)
• 5.4 Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026
• Exhibit 32: Chart on Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Antidepressant and antipsychotic drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Antidepressant and antipsychotic drugs - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Antidepressant and antipsychotic drugs - Year-over-year growth 2021-2026 (%)
• 5.5 Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026
• Exhibit 36: Chart on Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Antimicrobial and immunomodulatory drugs - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Antimicrobial and immunomodulatory drugs - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Antimicrobial and immunomodulatory drugs - Year-over-year growth 2021-2026 (%)
• 5.6 Market opportunity by Product
• Exhibit 40: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 42: Chart on Market share By Geographical Landscape 2021-2026 (%)
• Exhibit 43: Data Table on Market share By Geographical Landscape 2021-2026 (%)
• 7.2 Geographic comparison
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison
• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• 7.7 US - Market size and forecast 2021-2026
• Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)
• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
• 7.11 France - Market size and forecast 2021-2026
• Exhibit 78: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on France - Year-over-year growth 2021-2026 (%)
• 7.12 Market opportunity By Geographical Landscape
• Exhibit 82: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers
• 8.2 Market challenges
• 8.3 Impact of drivers and challenges
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026
• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview
• 9.2 Vendor landscape
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
• 9.3 Landscape disruption
• Exhibit 85: Overview on factors of disruption
• 9.4 Industry risks
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 87: Vendors covered
• 10.2 Market positioning of vendors
• Exhibit 88: Matrix on vendor position and classification
• 10.3 AIM ImmunoTech Inc.
• Exhibit 89: AIM ImmunoTech Inc. - Overview
• Exhibit 90: AIM ImmunoTech Inc. - Product / Service
• Exhibit 91: AIM ImmunoTech Inc. - Key offerings
• 10.4 Apotex Inc.
• Exhibit 92: Apotex Inc. - Overview
• Exhibit 93: Apotex Inc. - Product / Service
• Exhibit 94: Apotex Inc. - Key offerings
• 10.5 Bionpharma Inc.
• Exhibit 95: Bionpharma Inc. - Overview
• Exhibit 96: Bionpharma Inc. - Product / Service
• Exhibit 97: Bionpharma Inc. - Key offerings
• 10.6 Cadila Pharmaceuticals Ltd.
• Exhibit 98: Cadila Pharmaceuticals Ltd. - Overview
• Exhibit 99: Cadila Pharmaceuticals Ltd. - Business segments
• Exhibit 100: Cadila Pharmaceuticals Ltd. - Key offerings
• Exhibit 101: Cadila Pharmaceuticals Ltd. - Segment focus
• 10.7 Hikma Pharmaceuticals Plc
• Exhibit 102: Hikma Pharmaceuticals Plc - Overview
• Exhibit 103: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 104: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 105: Hikma Pharmaceuticals Plc - Segment focus
• 10.8 Lupin Ltd.
• Exhibit 106: Lupin Ltd. - Overview
• Exhibit 107: Lupin Ltd. - Product / Service
• Exhibit 108: Lupin Ltd. - Key news
• Exhibit 109: Lupin Ltd. - Key offerings
• 10.9 Pfizer Inc.
• Exhibit 110: Pfizer Inc. - Overview
• Exhibit 111: Pfizer Inc. - Product / Service
• Exhibit 112: Pfizer Inc. - Key news
• Exhibit 113: Pfizer Inc. - Key offerings
• 10.10 Sun Pharmaceutical Industries Ltd.
• Exhibit 114: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 115: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 116: Sun Pharmaceutical Industries Ltd. - Key offerings
• 10.11 Teva Pharmaceutical Industries Ltd.
• Exhibit 117: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 118: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 119: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 120: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 121: Teva Pharmaceutical Industries Ltd. - Segment focus
• 10.12 Viatris Inc.
• Exhibit 122: Viatris Inc. - Overview
• Exhibit 123: Viatris Inc. - Business segments
• Exhibit 124: Viatris Inc. - Key offerings
• Exhibit 125: Viatris Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report
• 11.2 Inclusions and exclusions checklist
• Exhibit 126: Inclusions checklist
• Exhibit 127: Exclusions checklist
• 11.3 Currency conversion rates for US$
• Exhibit 128: Currency conversion rates for US$
• 11.4 Research methodology
• Exhibit 129: Research methodology
• Exhibit 130: Validation techniques employed for market sizing
• Exhibit 131: Information sources
• 11.5 List of abbreviations
• Exhibit 132: List of abbreviations